Allogene Therapeutics, Inc. (ALLO) vs Cerus Corporation (CERS)
A side-by-side comparison of Allogene Therapeutics, Inc. and Cerus Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALLO
Allogene Therapeutics, Inc.
$1.46HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
CERS
Cerus Corporation
$2.36HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
Total return — ALLO vs CERS
growth of $100 · dividends reinvested · last 8yALLO -94.0% (-29.6%/yr)CERS -63.9% (-12.0%/yr)CERS compounded faster over this window
Log scale — wide-divergence pair
ALLO CERS
ALLO vs CERS: by the numbers
- •ALLO is the larger company ($504M vs $475M market cap).
- •Both run net losses; CERS's is the smaller (-3.06% vs -3566.68% net margin).
- •CERS grew revenue faster over the past five years (15.74% vs -34.47% CAGR).
Metrics side by side
Valuation
| Metric | ALLO | CERS |
|---|---|---|
| P/S ratio | 108.60 | 2.14 |
| P/B ratio | 1.16 | 6.78 |
| EV / EBITDA | N/A | 8081.97 |
Profitability
| Metric | ALLO | CERS |
|---|---|---|
| Gross margin | 0.00% | 52.05% |
| Operating margin | 0.00% | -0.73% |
| Net margin | -3566.68% | -3.06% |
| ROE | -37.94% | -9.69% |
| ROIC | -34.79% | -1.08% |
Growth (annualized)
| Metric | ALLO | CERS |
|---|---|---|
| Revenue CAGR (5Y) | -34.47% | 15.74% |
| Total return CAGR (5Y) | -42.72% | -17.30% |
Frequently asked
- Which has grown faster, ALLO or CERS?
- Over the past five years, CERS grew revenue faster — ALLO at a -34.47% CAGR versus CERS at 15.74%.
- How have ALLO and CERS total returns compared?
- Over the past 5 years, ALLO delivered -42.72% and CERS delivered -17.30% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Allogene Therapeutics ROECerus ROEAllogene Therapeutics operating marginCerus operating marginAllogene Therapeutics revenue growthCerus revenue growthAllogene Therapeutics free cash flowCerus free cash flow
Allogene Therapeutics & Cerus appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.